Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent (NYSE: A) announced a quarterly cash dividend of 25.5 cents per share. The dividend is payable on Jan. 28, 2026 to shareholders of record at the close of business on Jan. 6, 2026. The company said timing and amounts of future dividends remain subject to the board of directors’ determination and approval.
Agilent reported $6.51 billion in revenue for fiscal year 2024 and employs approximately 18,000 people worldwide. The release includes customary forward-looking statement language about risks and uncertainties related to the dividend program.
Agilent Technologies (NYSE: A) announced the Altura Ultra Inert HPLC columns, a new product line aimed at biotherapeutics analysis including peptide GLP-1 and oligonucleotide workflows. The release highlights faster conditioning, improved peak shape, enhanced sensitivity, and a fully inert sample flow path designed for demanding QC and development labs.
Agilent claims up to 2x sensitivity, 3x signal-to-noise ratio, and, when paired with the Agilent 1290 Infinity III Bio LC, up to 30x higher peak area; an external test cited a ~30% sensitivity increase and reduced peak tailing on acidic peptides.
Agilent (NYSE: A) will participate in Citi’s 2025 Global Healthcare Conference on Dec. 4, 2025. Chief Enterprise Transformation Officer Tom Callihan and Head of Investor Relations Tejas Savant will take part in a fireside chat from 9:00 to 9:45 a.m. EDT in Miami.
A live audio webcast and replay will be available on Agilent’s investor relations website. Agilent reported $6.51 billion revenue in fiscal year 2024 and employs approximately 18,000 people worldwide.
Lunit (KRX:328130.KQ) and Agilent (NYSE:A) announced a nonexclusive collaboration on Sept 22, 2025 to co-develop AI-powered companion diagnostic (CDx) solutions for complex biomarker assays.
The partnership will combine Lunit's AI algorithms and Agilent's tissue-based diagnostic assays, initially targeting research and clinical-trial use to improve biomarker accuracy and support pharma CDx development. Lunit noted its FDA-cleared Lunit INSIGHT suite is used at over 7,000 medical institutions in more than 65 countries.
Agilent (NYSE: A) awarded an Agilent Research Catalyst (ARC) grant to the University of California, Davis on behalf of Professor Marie Heffern on November 12, 2025.
The award funds research using Agilent instrumentation (8900 ICP-QQQ, 6546 Q-TOF LC/MS, Infinity II LC) to study metal–peptide interactions in incretin-based therapeutics (GLP-1 receptor agonists). The project will apply LC-ICP-MS, native MS, and high-resolution peptide mapping to assess effects on drug stability, formulation, and bioactivity, aiming to build a predictive framework to inform formulation strategies and reduce degradation.
TORM plc (NASDAQ: TRMD / TRMD A) completed a capital increase of 2,395,426 A-shares (nominal USD 23,954.26) on Nov 12, 2025 related to delivery of one LR2 vessel and exercise of Restricted Share Units (RSUs).
Key items: 748,569 shares were issued to settle a USD 17.0m allocated loan note for the 2010-built LR2 (USD 22.71 per A-share). 1,646,857 A-shares were issued on RSU exercises (1,558,790 at DKK 0.07 and 88,067 at DKK 140.2). New shares are subject to a 40-day lock-up with Regulation S resale exceptions.
Post-increase share capital: USD 1,003,478.57 divided into 100,347,855 A-shares, one B-share and one C-share.
Agilent (NYSE: A) will release fourth-quarter fiscal 2025 results after market close on Monday, Nov. 24, 2025. The company will host a listen-only conference call webcast at 1:30 p.m. PST the same day, with a recording available on Agilent's investor website for 90 days.
Agilent reported $6.51 billion revenue in fiscal 2024 and employs approximately 18,000 people. Webcast access is via the Events section of Agilent's Investor Relations site; investor and media contacts are provided for follow-up.
Agilent (NYSE: A) named Adam S. Elinoff as chief financial officer, effective Nov. 17, 2025. Elinoff joins from Amgen after 19 years, most recently serving as vice president of finance and treasurer, and previously managing a $6 billion P&L across 67 markets as regional CFO. Agilent reported $6.51 billion revenue for fiscal 2024. Rodney Gonsalves will return to his role as corporate controller and principal accounting officer.
The appointment emphasizes Elinoff’s experience in finance, strategy, M&A, and global transformations as Agilent executes its Ignite Operating System.
Agilent Technologies (NYSE: A) has launched its new Insight Series Alarm Resolution Systems for airport security screening, featuring the Insight300M and InsightBLS models. These advanced liquid explosive detection systems (LEDs) are designed to screen liquids, aerosols, and gels (LAGs) at airport checkpoints.
The systems boast the industry's lowest false alarm rate and rapid scan times, capable of identifying threats through complex barriers and multi-layered materials. A key feature is their future-proof design, allowing updates through software upgrades without hardware replacement. The launch builds on Agilent's 2017 acquisition of Cobalt Light Systems and will be showcased at the International Security Expo in London.
Agilent Technologies (NYSE: A) has launched the new Altura Ultra Inert HPLC Columns, designed specifically for biotherapeutics applications. The innovative columns demonstrate up to 2x sensitivity and 3x signal-to-noise ratio compared to competitors, while achieving up to 30x higher peak area when used with Agilent's 1290 Infinity III Bio LC.
The Altura line addresses critical needs in biopharma testing, particularly for peptide GLP-1 and oligonucleotide therapeutic development. Early testing shows a 30% increase in sensitivity and reduced peak tailing for acidic peptides and excipients analysis, offering superior chromatographic performance through faster conditioning, improved peak shape, and enhanced sensitivity.